This is further supported by concurrent increases in leukocyte population gene sets (CD45) being upregulated in cell profiling analysis derived from this gene expression panel, as well as by inferred increases in tumor-infiltrating lymphocytes with a skewed Th1 T cell and dendritic cell (DC) profile compared to PBS weeks after therapeutic administration (Figure 3E). The gene discussed is PTPRC; the disease is neoplasm.